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Purpose: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) often occur
concomitantly, presenting diagnostic and therapeutic challenges for clinicians. We examined
the characteristics of patients prescribed adequate versus inadequate therapy within 3 months
after newly diagnosed comorbid COPD or HF.
Patients and Methods: Eligible patients in longitudinal UK electronic medical record
databases had pre-existing HF and newly diagnosed COPD (2017 GOLD groups B/C/D) or pre-
existing COPD and newly diagnosed HF. Adequate COPD therapy was defined as long-acting
bronchodilator(s) with/without inhaled corticosteroid; adequate HF therapy was defined as beta-
blocker plus angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker.
Results: Of 2439 patients with HF and newly diagnosed COPD (mean 75 years, 61% men),
adequate COPD therapy was prescribed for 726 (30%) and inadequate for 1031 (42%); 682
(28%) remained untreated for COPD. Adequate (vs inadequate) COPD therapy was less
likely for women (35%) than men (45%), smokers (36%) than ex-/non-smokers (45%), and
non-obese (41%) than obese (47%); spirometry was recorded for 57% prescribed adequate
versus 35% inadequate COPD therapy. Of 12,587 patients with COPD and newly diagnosed
HF (mean 75 years, 60% men), adequate HF therapy was prescribed for 2251 (18%) and
inadequate for 5332 (42%); 5004 (40%) remained untreated for HF. Adequate (vs inade-
quate) HF therapy was less likely for smokers (27%) than ex-/non-smokers (32%) and non-
obese (30%) than obese (35%); spirometry was recorded for 65% prescribed adequate versus
39% inadequate HF therapy.
Conclusion: Many patients with comorbid COPD/HF receive inadequate therapy after new
diagnosis. Improved equity of access to integrated care is needed for all patient subgroups.
Keywords: beta-blocker, long-acting bronchodilator, integrated care, multimorbidity
Plain Language Summary
The ageing of populations globally has brought attention to the issue of multimorbidity as
a common concern and area for prioritization of research. In older individuals, COPD and
heart failure (HF) often occur concomitantly, presenting diagnostic and therapeutic chal-
lenges for clinicians. However, published guidance on the treatment of comorbid COPD and
HF is sparse, as consensus guidelines focus on the treatment of individual conditions. We
used well-managed, longitudinal medical record databases in the UK to examine the demo-
graphic and clinical characteristics of patients prescribed adequate versus inadequate therapy
within 3 months after newly diagnosed comorbid COPD or HF.
We observed low levels of guidelines-recommended prescribing for therapy of new
COPD and new HF diagnoses among patients with comorbid COPD and HF. Only one-
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third (30%) of patients in the HF-new COPD cohort were pre-
scribed adequate COPD therapy within 3 months of the COPD
diagnosis, and less than one-fifth (18%) of patients in the COPD-
new HF cohort were prescribed adequate HF therapy within 3
months of the HF diagnosis. Patients most likely to be prescribed
inadequate COPD therapy included women, current smokers, and
non-obese patients, and those most likely to be prescribed inade-
quate HF therapy included current smokers and non-obese
patients.
Further work is needed to understand the reasons for under-
prescribing and to address them. In addition, readily accessible
clinical guidance is needed that addresses not only the diagnosis
but the care of patients with comorbid COPD and HF. Finally,
improved equity of access to integrated care for all patient sub-
groups with comorbid COPD and HF is needed, particularly for
women, smokers, and non-obese patients.
Introduction
The ageing of populations globally has brought attention to
the issue of multiple morbidities as a common concern and
area for prioritization of research.1–3 In older individuals,
chronic obstructive pulmonary disease (COPD) and heart
failure (HF) often occur concomitantly.4,5 The reported pre-
valence of HF in patients with COPD ranges from 20% to
70%,4 with 2.6 times greater odds of HF in patients with
COPD versus without COPD calculated in a recent meta-
analysis,6 and the presence of COPD is a significant risk
factor for HF, with relative risks ranging from 1.5 to 6.8,
depending on age, reported in a large population-based study
in the UK.7 The reported prevalence of COPD in patients
with HF ranges from 9% to 52%.8
Patients with comorbid COPD and HF have a worse
long-term prognosis than those with either condition
alone.9 The presence of COPD is a predictor of hospitali-
zation and death from cardiovascular events,10–13 while
the presence of HF increases the risk of death in patients
with COPD.14,15 However, patients with comorbid COPD
and HF present both diagnostic and therapeutic challenges
for clinicians. Overlapping signs and symptoms and simi-
lar risk factors, such as smoking, older age, and inactivity,
contribute to the diagnostic challenge,16–18 particularly as
both COPD and HF cause breathlessness.19
The focus of published guidelines and management
recommendations tends to be on single conditions, thus
on either COPD or HF, rather than on the optimal manage-
ment of comorbid COPD and HF, although the need to
treat comorbidities on their merit is increasingly
acknowledged.4,18,20–23 For example, the Global initiative
for chronic Obstructive Lung Disease (GOLD) strategy
documents since 2011 have noted that there is no evidence
either to treat HF differently for patients with comorbid
COPD nor to treat COPD differently in the presence of
HF.4 Similarly, according to the European Society of
Cardiology guidelines since 2008, beta-blockers are not
contraindicated for HF in patients with COPD, although
cardioselective beta-blockers are recommended over non-
selective beta-blockers.23,24
Nonetheless, in light of the opposing pharmacological
effects of beta-blockers and beta-agonists, there are concerns
that health-care providers may be reluctant to prescribe long-
acting bronchodilators (LABD), in particular long-acting
beta-agonists (LABAs), to treat COPD for patients with
comorbid HF.16 Also, there is evidence that health-care pro-
viders are reluctant to prescribe beta-blockers to treat HF in
patients with comorbid COPD.25,26 Many gaps remain in our
understanding of the optimal management of patients with
comorbid COPD and HF,9 and a better understanding of real-
life treatment and factors affecting treatment adequacy for
these patients is needed.
As part of a broader program to look at current treatment
and outcomes for patients with comorbid COPD and HF, our
objectives in this historical cohort study were to describe and
contrast the demographic and clinical characteristics of 1)
patients with pre-existing HF and a new diagnosis of COPD
who were prescribed adequate versus inadequate COPD
therapy and 2) patients with pre-existing COPD and a new
diagnosis of HF who were prescribed adequate versus inade-
quate HF therapy according to guidelines.
Methods
Data Sources
We used two large, well-established UK databases con-
taining anonymized, longitudinal medical record data for
this study: the Clinical Practice Research Datalink
(CPRD)27 and the Optimum Patient Care Research
Database (OPCRD).28 Both databases contain long-term
electronic medical record (EMR) data and are frequently
used for pharmacoepidemiological research.
The CPRD is a computerized primary care database
containing de-identified, longitudinal data from more than
600 subscribing general practices throughout the UK,
representing about 5 million patients with active medical
records or 7% of the UK population.27 A practice-based
quality marker, the “up-to-standard date,” is generated by
the CPRD for each subscribing practice, and data after the
practice up-to-standard date are considered to be
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acceptable, research quality, prospectively recorded data.
The CPRD is a governmental, not-for-profit research ser-
vice, jointly funded by the NHS National Institute for
Health Research (NIHR) and the Medicines and
Healthcare products Regulatory Agency (MHRA), a part
of the Department of Health.
The OPCRD comprises data captured for clinical ser-
vice evaluation by Optimum Patient Care, a not-for-profit
organization that offers free respiratory clinical evalua-
tions with the aim of improving patient outcomes through
medical research and services, providing evidence-based
recommendations to UK general practices through
bespoke software and practice reports.28 At the time of
the study, the OPCRD included anonymous, longitudinal
medical records for over 2.8 million patients from more
than 550 primary care practices across the UK. The use of
the OPCRD for research purposes has approval from the
NHS Health Research Authority and is governed by the
Anonymous Data Ethics Protocols and Transparency
(ADEPT) committee, the independent scientific advisory
committee for the OPCRD.
The CPRD and OPCRD datasets used in this study
were first constructed separately, and then, because
a small number of family practices contribute data to
both databases, we excluded duplicate patients by check-
ing for overlap in key demographics (such as year of birth
and sex), blood test results, and test dates before pooling
for the analyses, as previously described.29
The study was registered with The European Union elec-
tronic Register of Post-Authorisation Studies
(EUPAS12987)30 and was conducted according to recom-
mended procedures for observational research.31,32 Research
governance approval was obtained from each database for
this study (CPRD ISAC reference number 16_039 and
ADEPT Approval Reference PROTOCOL1116). Patient
data remained anonymized throughout the analyses.
Data Statement
The datasets supporting the conclusions of this article were
derived from the Clinical Practice Datalink (http://www.
cprd.com) and the Optimum Patient Care Research
Database (http://opcrd.co.uk/). We do not have permission
to give public access to these datasets; however, research-
ers may request access for their own purposes.
Study Design and Patients
We conducted two descriptive cohort analyses drawing on
mutually exclusive, combined datasets drawn from the
CPRD and OPCRD. The first analysis examined and com-
pared the characteristics of patients with pre-existing HF and
a new COPD diagnosis who were prescribed adequate versus
inadequate COPD therapy within the first 3 months after the
COPD diagnosis. The second analysis examined and com-
pared the characteristics of patients with pre-existing COPD
and a new HF diagnosis who were prescribed adequate
versus inadequate HF therapy within the first 3 months
after the HF diagnosis. The study period was 1988 through
May 2015, and the “index date” was defined as 3 months
after the new COPD or new HF diagnosis.
To be eligible for this study, patients had to have
a diagnosis of HF recorded at any time followed by
a new COPD diagnosis recorded at any time after the
first HF diagnosis (HF-new COPD cohort) or the converse,
namely, a recorded COPD diagnosis followed by a new
HF diagnosis (COPD-new HF cohort). The diagnoses of
COPD and HF were identified by recorded diagnostic
Read codes, the coding system used by the UK National
Health Service (NHS),33 as specified by the NHS Quality
and Outcomes Framework (QOF), which provides incen-
tives for key measures to be recorded in primary care
EMRs.34,35 The inclusion of COPD as a clinical area was
effected at the time of QOF implementation in 2004/2005,
and HF entered QOF in 2006/2007.
To be eligible, patients were 40 years or older at 3
months after the new diagnosis (COPD or HF, respec-
tively, depending on the cohort). We required that they
had continuous, recorded practice data during a total of 2
years plus 3 months, including a baseline year beginning
1 year before the new COPD or new HF diagnosis and an
outcome year beginning 3 months after the new COPD
diagnosis or new HF diagnosis, respectively. Patients who
died during the outcome year were not excluded.
Patients in the HF-new COPD cohort were limited to
those with COPD designated as GOLD group B, C, or
D (2017 criteria36). The GOLD group was determined
using exacerbation and mMRC data recorded closest to
and within 5 years before or after the index date. We
excluded patients in GOLD group A because their symp-
toms can be mild enough such that minimal therapy is
required and adequacy of therapy could be difficult to
judge. In addition, patients were excluded if they had
any prior asthma, resolved asthma, or other chronic
respiratory diagnoses before the COPD diagnosis.
Because the actual date of a diagnosis may occur slightly
earlier than when first recorded, the date of COPD diag-
nosis was set to the first prescription of an LABD if that
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prescription was in the month preceding the first COPD
Read code. It was not possible to use a similar definition
for HF because of the lack of a HF-specific drug; however,
patients in the COPD-new HF cohort had to have recorded
evidence of COPD or HF therapy.
Endpoint Definitions
Patients were assigned to an adequate, inadequate, or no-
therapy group based on primary care prescribing within
the first 3 months after the new diagnosis. We then com-
pared the demographic and clinical characteristics of
patients who were prescribed adequate versus inadequate
therapy for a new COPD diagnosis (HF-new COPD
cohort) or for a new HF diagnosis (COPD-new HF
cohort).
Adequate therapy for COPD in GOLD groups B, C,
and D was defined as one or more prescriptions for an
LABD, including a LABA, a long-acting muscarinic
antagonist (LAMA), or LABA plus LAMA, with or with-
out ICS, while inadequate therapy for COPD was defined
as prescription(s) for only short-acting bronchodilators
(SABDs).5,20,36 No COPD therapy was defined as no
SABD or LABD prescription.
For HF, adequate therapy was defined as one or more
prescriptions for a beta-blocker plus an angiotensin-
converting enzyme (ACE) inhibitor and/or an angiotensin
receptor blocker (ARB).21–23 Inadequate therapy for HF
was defined as an ARB plus ACE inhibitor (no beta-
blocker) or monotherapy with a beta-blocker, ARB, or
ACE inhibitor. No therapy was defined as no recorded
prescription for any of these three drug classes.
Statistical Analyses
We conducted descriptive analyses of patient demographics,
comorbidities, and indicators of disease severity, summariz-
ing categorical data as number (percentage) and continuous
and count data as mean (SD) or median (interquartile range
[IQR]), as appropriate. For baseline variables with missing
data, the percentages of patients with available data were
noted.
Baseline demographic and clinical characteristics of
patients prescribed adequate versus inadequate COPD
therapy after a new COPD diagnosis (with pre-existing
HF) were tabulated together, and demographic and clinical
characteristics of those prescribed adequate versus inade-
quate HF therapy after a new HF diagnosis (with pre-
existing COPD) were tabulated together. Comparisons
between adequate and inadequate therapy groups were
made using the Mann–Whitney U-test or χ2, as appropri-
ate, with p-values.
Analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC).
Results
Pre-Existing HF and New Diagnosis of
COPD: Adequate versus Inadequate
COPD Therapy
A total of 2439 eligible patients with pre-existing HF and
a new COPD diagnosis (GOLD groups B, C, or D) were
identified from the CPRD and OPCRD (Figure 1). Overall,
the mean patient age was 75 years, and 61% of patients
were male. By the end of 3 months after the new COPD
diagnosis (the index date), 726 patients (30%) had been
prescribed adequate therapy for COPD, as per the study
definition of prescription(s) for LABD(s) ± ICS; 1031
patients (42%) were inadequately treated (prescribed only
SABDs); and 682 patients (28%) remained untreated (no
SABD or LABD prescription).
Figure 1 Flow chart depicting selection of patients with heart failure and new
COPD diagnosis.
Abbreviations: CPRD, Clinical Practice Research Datalink; GOLD, Global initia-
tive for chronic Obstructive Lung Disease; LABD, long-acting bronchodilator;
OPCRD, Optimum Patient Care Research Database.
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The mean patient age was 75 years in both adequate and
inadequate therapy groups, and approximately half of
patients in each group were identified as having COPD in
GOLD group B, one-third in GOLD C, and one-fifth in
GOLD D (Table 1). In the side-by-side comparison between
adequate and inadequate therapy groups (Figure 2), the sub-
groups of patients who were proportionately less likely to be
prescribed adequate COPD therapy included women (35%
prescribed adequate COPD therapy vs 45% of men), current
smokers (36% vs 46% and 43% of ex- and non-smokers,
respectively), and non-obese patients (41% vs 47% of obese
patients). In addition, of the patients prescribed adequate
therapy for new COPD, 57% had recorded spirometry,
while of those prescribed inadequate therapy for new
COPD, only 35% had recorded spirometry. Of the patients
with severe breathlessness (mMRC score of 3 or 4), 46%
(232/504) were prescribed adequate COPD therapy as com-
pared with 39% (494/1253) of those with mMRC score of
0–2 (Table 1). The median year of the index date was earlier
for patients prescribed inadequate COPD therapy (2004 vs
2009 for adequate therapy).
A higher percentage of patients had other common
comorbidities in the adequate therapy group as compared
with the inadequate therapy group (Table 1).
Pre-Existing COPD and New Diagnosis of
HF: Adequate versus Inadequate HF
Therapy
A total of 12,587 eligible patients with pre-existing COPD
and new HF diagnosis were identified (Figure 3). Overall
baseline patient characteristics were similar to those of the
patients with pre-existing HF and new COPD diagnosis: the
mean age was 75 years, and 60% were male. At the end of 3
months after the new HF diagnosis, 2251 (18%) were pre-
scribed adequate therapy for HF, as per the study definition of
prescription(s) for a beta-blocker plus an ACE inhibitor and/
or an ARB; 5332 patients (42%) were prescribed inadequate
therapy (any other combination of these drug classes); and
5004 patients (40%) remained untreated.
There were differences in sex ratios and mean ages of
patients in adequate versus inadequate therapy groups; how-
ever, these differences were not numerically large, with mean
ages 73.3 versus 74.5 years, respectively, and as 28% of
women and 31% of men received adequate HF therapy.
Other differences between adequate versus inadequate HF
therapy groups were numerically larger (Table 2). For
Table 1 Demographic and Clinical Characteristics of Patients
with Pre-Existing Heart Failure (HF) Who Were Prescribed
Adequate versus Inadequate COPD Therapy Within 3 Months
of a New COPD Diagnosis (HF-New COPD Cohort)
Variable Adequate
COPD
Therapy
(n = 726)
Inadequate
COPD
Therapy
(n = 1031)
p-Value
Age, mean (SD) 74.8 (9.0) 75.4 (8.6) 0.35
40–<70 years 190 (26.2) 243 (23.6) 0.23
≥70 years 536 (73.8) 788 (76.4)
Index date year, median (IQR) 2009
(2007–2012)
2004
(2000–2008)
n/a
Smoking status data availablea,b 719 (99.0) 979 (95.0)
Body mass index data availablea 718 (98.9) 937 (90.9)
CCI score, median (IQR) 7 (4–17) 7 (4–17) 0.012
mMRC score data availablea,c 726 (100) 1031 (100)
mMRC score of 0 (n=50) 28 (56.0) 22 (44.0) <0.001
mMRC score of 1 (n=537) 182 (33.9) 355 (66.1)
mMRC score of 2 (n=666) 284 (42.6) 382 (57.4)
mMRC score of 3 (n=395) 187 (47.3) 208 (52.7)
mMRC score of 4 (n=109) 45 (41.3) 64 (58.7)
2017 GOLD group data
availabled
726 (100) 1031 (100)
GOLD B 373 (51.4) 507 (49.2) <0.001
GOLD C 210 (28.9) 377 (36.6)
GOLD D 143 (19.7) 147 (14.3)
FEV1 data available
e 416 (57.3) 358 (34.7) <0.001
Median %predicted (IQR) 56 (43–68) 60 (48–70) <0.001
GERD dx/tx in pre-index year 314 (43.3) 319 (30.9) <0.001
IHD diagnosis ever prior 536 (73.8) 737 (71.5) 0.28
Diabetes dx/tx in pre-index year 154 (21.2) 174 (16.9) 0.022
Hypertension diagnosis ever prior 444 (61.2) 485 (47.0) <0.001
Chronic renal disease diagnosis 303 (41.7) 213 (20.7) <0.001
Concomitant diuretic script(s),
yes
590 (81.3) 850 (82.4) 0.528
NYHA classification/proxy
availablef
409 (56.3) 368 (35.7)
NYHA Class I 83 (20.3) 62 (16.8) 0.28
NYHA Class II 165 (40.3) 167 (45.4)
NYHA Class III 131 (32.0) 120 (32.6)
NYHA Class IV 30 (7.3) 19 (5.2)
Notes:Data are presented as n (%) unless otherwise indicated. Comparisons made using χ2
test forcategorical values andMann–WhitneyU-test forcontinuousorcount variables. aPatient
percentages for mMRC are presented as row percentages; the other variables are calculated
using columnpercentages. bSmoking statuswasdeterminedusing theRead code closest to and
<5 years before the index date (3 months after new COPD diagnosis). cmMRC score was
definedas theReadcoderecordedclosest toand<5yearsbefore (orotherwise<5years after)
the index date. dGOLD group was calculated using exacerbation and mMRC data recorded
closest to andwithin 5 years before or after the indexdate (2017 criteria36). eFEV1 determined
closest to and within 5 years before the index date. fNYHA classification determined by Read
code closest to andwithin 5 years before the index date. NYHA datawere limited in primary
care medical records so breathlessness Read codes were used as proxies for NYHA class.
Abbreviations: CCI, Charlson comorbidity index; GERD, gastroesophageal reflux dis-
ease; GOLD, Global initiative for chronic Obstructive Lung Disease; IHD, ischemic heart
disease; IQR, interquartile range; mMRC, modified Medical Research Council dyspnea
scale; n/a, not available; NYHA, New York Heart Association; script, prescription.
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example, 27% of current smokers versus 32% of ex-smokers
and 32% of non-smokers, and 30% of non-obese versus 35%
of obese patients were prescribed adequate HF therapy
(Figure 4).Of those prescribed adequate HF therapy, 65%
had recorded spirometry versus only 39% of those receiving
inadequate therapy for newHFdiagnosis. Of the patientswith
severe breathlessness (mMRC score of 3 or 4), 34% (377/
1123)were prescribed adequateHF therapy as comparedwith
35% (1580/4480) with an mMRC score of 0–2. As for the
HF-new COPD cohort, the median year of the index date was
earlier for patients prescribed inadequateHF therapy (2004 vs
2010 for adequate therapy).
Also, similar to the HF-new COPD cohort, among patients
with COPD and newly diagnosed HF, other common comor-
bidities were more frequent in the adequate therapy group as
compared with the inadequate therapy group (Table 2).
Discussion
We identified low levels of guidelines-recommended prescrib-
ing for therapy of new COPD and new HF diagnoses among
UK patients with comorbid COPD and HF in this historical
cohort study. Only one-third (30%) of patients in the HF-new
COPD cohort were prescribed adequate COPD therapy within
3 months of the COPD diagnosis, and less than one-fifth
(18%) of patients in the COPD-new HF cohort were pre-
scribed adequate HF therapy within 3 months of the HF
diagnosis. Women, current smokers, and non-obese patients
were proportionately less likely to be prescribed adequate
COPD therapy, whilst current smokers and non-obese patients
were less likely to receive adequate HF therapy.
We broadly defined adequate therapy for COPD (exclud-
ing GOLD group A) as prescription(s) for LABD(s) with or
without ICS, per GOLD guidelines.4,5 In a prior study of
COPD prescribing (comorbid HF not assessed), factors that
influenced the initial prescription in COPD were comorbid
asthma, exacerbation history, symptoms, and lung
function.37 Breathlessness is a common finding in patients
even with stable HF and COPD,19 and the presence of
dyspnea may encourage prescribing of bronchodilators.
However, the fact that some patient subgroups with newly
diagnosed COPD and pre-existing HF (eg, women, current
smokers, non-obese patients) were less likely to be pre-
scribed adequate COPD therapy in the form of LABDs
suggests a need to focus clinical education on COPD therapy
for these subgroups. In addition, a large proportion of
patients who were prescribed inadequate therapy had no
recorded spirometry, although we note that spirometry is
often under-recorded in the community setting.38,39
With regard to prescribing of adequate HF therapy (beta-
blocker plus an ACE inhibitor and/or an ARB), our findings
are in line with prior observational study findings of
a reluctance to prescribe beta-blockers to patients with
Figure 2 Sex, smoking status, and body mass index categories of patients with pre-existing heart failure (HF) who were prescribed adequate versus inadequate COPD
therapy within 3 months of a new COPD diagnosis (HF-new COPD cohort). χ2 test p≤0.001 for comparisons between women and men and among smoking status
categories; p=0.016 for comparisons between BMI categories. Smoking status was determined using the Read code closest to and <5 years before the index date (3 months
after new COPD diagnosis).
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comorbid COPD and HF.12,25 Even for patients hospitalized
for HF, those with comorbid COPD (vs no comorbid COPD)
are reportedly less likely to be prescribed beta-blockers and
ACE inhibitors/ARBs at the time of discharge from the
hospital.12,39 In our study, current smokers and non-obese
patients were less likely to receive adequate HF therapy, and
again we found no recorded spirometry within the prior 5
years for a large proportion of patients (61%) with pre-
existing COPD who were then prescribed suboptimal HF
therapy after a new HF diagnosis.
Much of prior work pertains to patients with comorbid
COPD and HF who experience COPD exacerbations or are
hospitalised.38–41 The results of this study add to the limited
information available on prescribing practices for patients
cared for primarily outside of the hospital setting25,39,42 and
may potentially raise awareness of the optimal treatment of
patients with COPD and HF. The data contained in the CPRD
and OPCRD largely pertain to people treated in general
practice, as few UK primary care patients with COPD attend
Figure 3 Flow chart depicting selection of patients with COPD and new heart
failure diagnosis.
Abbreviations: CPRD, Clinical Practice Research Datalink; GOLD, Global initia-
tive for chronic Obstructive Lung Disease; LABD, long-acting bronchodilator;
OPCRD, Optimum Patient Care Research Database.
Table 2 Demographic and Clinical Characteristics of Patients
with Pre-Existing COPDWho Were Prescribed Adequate versus
Inadequate Heart Failure (HF) Therapy Within 3 Months of
a New HF Diagnosis (COPD-New HF Cohort)
Variable Adequate
HF
Therapy (n
= 2251)
Inadequate
HF Therapy
(n = 5332)
p-Value
Age, mean (SD) 73.3 (9.0) 74.5 (8.7) <0.001
40 – <70 years 753 (33.5) 1444 (27.1) <0.001
≥70 years 1498 (66.5) 3888 (72.9)
Index date year, median (IQR) 2010
(2006–2012)
2004
(2000–2008)
n/a
Smoking status data availablea,b 2192 (97.4) 4925 (92.4)
Body mass index data availablea 2199 (97.7) 4773 (89.5)
CCI score, median (IQR) 13 (13–18) 13 (13–17) <0.001
mMRC score data availablea,c 1957 (86.9) 3646 (68.4)
mMRC score of 0 (n=332) 183 (55.1) 149 (44.9) <0.001
mMRC score of 1 (n=2840) 882 (31.1) 1958 (68.9)
mMRC score of 2 (n=1308) 515 (39.4) 793 (60.6)
mMRC score of 3 (n=861) 302 (35.1) 559 (64.9)
mMRC score of 4 (n=262) 75 (28.6) 187 (71.4)
2017 GOLD group data
availabled
1957 (86.9) 3646 (68.4) 0.002
GOLD A 700 (35.8) 1299 (35.6)
GOLD B 579 (29.6) 937 (25.7)
GOLD C 365 (18.7) 808 (22.2)
GOLD D 313 (16.0) 602 (16.5)
FEV1 data available
e 1470 (65.3) 2087 (39.1) <0.001
Median %predicted (IQR) 59 (46–71) 54 (41–67) <0.001
GERD dx/tx in pre-index year 999 (44.4) 1638 (30.7) <0.001
IHD diagnosis ever prior 1654 (73.5) 3285 (61.6) <0.001
Diabetes dx/tx in pre-index year 458 (20.3) 785 (14.7) <0.001
Hypertension diagnosis ever prior 1354 (60.2) 2570 (48.2) <0.001
Chronic renal disease diagnosis 685 (30.4) 824 (15.5) <0.001
Concomitant diuretic script(s) 1598 (71.0) 4013 (75.3) <0.001
NYHA classification/proxy availablef 1334 (59.3) 1562 (29.3)
NYHA Class I 537 (40.3) 452 (28.9) <0.001
NYHA Class II 447 (33.5) 530 (33.9)
NYHA Class III 299 (22.4) 479 (30.7)
NYHA Class IV 51 (3.8) 101 (6.5)
Notes:Data are presented as n (%) unless otherwise indicated. Comparisons made using χ2
test forcategorical values andMann–WhitneyU-test forcontinuousorcount variables. aPatient
percentages for mMRC are presented as row percentages; the other variables are calculated
using columnpercentages. bSmoking statuswasdeterminedusing theRead code closest to and
<5 years before the index date (3months after newHF diagnosis). cmMRC scorewas defined
as the Read code recorded closest to and <5 years before (or otherwise <5 years after) the
indexdate. dGOLDgroupwas calculatedusingexacerbationandmMRCdata recordedclosest
to andwithin 5 years beforeor after the indexdate (2017 criteria36). eFEV1 determined closest
to and within 5 years before the index date. fNYHA classification determined by Read code
closest to and within 5 years before the index date. NYHA datawere limited in primary care
medical records so breathlessness Read codes were used as proxies for NYHA class.
Abbreviations: CCI, Charlson comorbidity index; GERD, gastroesophageal reflux
disease; GOLD, Global initiative for chronic Obstructive Lung Disease; IHD,
ischemic heart disease; IQR, interquartile range; mMRC, modified Medical
Research Council dyspnea scale; n/a, not available; NYHA, New York Heart
Association; script, prescription.
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secondary care.43 Interestingly, we found that a greater per-
centage of patients in both adequate therapy groups, as com-
pared with the inadequate therapy groups, had other common
comorbidities, including gastroesophageal reflux disease,
diabetes, hypertension, and chronic renal disease. We do
not have definitive explanations for this finding, although
the higher rate of adequate therapy for these patients may
reflect a multidisciplinary management of patients with mul-
timorbidity. Many unanswered questions remain regarding
optimal therapy for and reasons for under-treatment of
comorbid COPD and HF in general practice.44
The strengths of this descriptive study include the use
of long-term longitudinal data from quality-controlled UK
databases frequently used for pharmacoepidemiologic
research.7,45,46 These findings illustrate real-life prescrib-
ing patterns for large, representative patient cohorts in the
UK. Moreover, the institution of the Quality and
Outcomes Framework in 2004 provides incentives for
recording of key disease-related measures in primary
care EMRs, which has improved the recording of variables
such as smoking status, recorded for >93% of patients in
each cohort.34 Quint et al45 studied the accuracy of COPD
diagnoses in the CPRD from 2004 to 2012 and found that
COPD diagnostic codes accurately identified patients with
COPD, with only marginally improved accuracy if
recorded spirometry or prescribed COPD medications
were used to confirm the COPD diagnosis. The median
index date years were later for the adequate therapy
groups, possibly suggesting improvements in prescribing
practices over time that may have been led by changes in
diagnostic criteria, guidelines, and the availability of
newer treatments.
The CPRD and OPCRD data are recorded for clinical
and routine use, however, rather than specifically for
research purposes. Whilst smoking status was recorded
for the majority of patients, the proportion of missing
data for some patient groups was high for certain vari-
ables. For example, FEV1 data was not available for 65%
of patients in the inadequate therapy group (vs 43% of the
adequate therapy group) of the HF-new COPD cohort, and
FEV1 and mMRC data were missing for 61% and 32% of
patients, respectively, in the inadequate therapy group (vs
35% and 13%, respectively, of the adequate therapy group)
of the COPD-new HF cohort. Moreover, there are limita-
tions to the use of EMR data, as not all patients had
definitive tests; as noted, many were missing spirometry
results, and not all would have had an echocardiogram.
Spirometry results that were recorded as free text and not
entered as coded data were not included in our data, which
could at least partially explain data missingness. Other
study limitations are that we applied the GOLD 2017
criteria to evaluate prescribing practices before 2017, and
we used only the mMRC to determine GOLD groups, as
Figure 4 Sex, smoking status, and body mass index categories of patients with pre-existing COPD who were prescribed adequate versus inadequate heart failure (HF)
therapy within 3 months of a new HF diagnosis (COPD-new HF cohort). χ2 test p=0.003 for comparisons between women and men; p<0.001 for comparisons among
smoking status categories and between BMI categories.
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COPD assessment test results were not included in these
earlier EMR data.
Some people may have been misdiagnosed as having HF
and later correctly diagnosed as having COPD; however, the
retrospective study design does not allow us to disentangle
this possibility. In addition, as information on left ventricular
ejection fraction was lacking, we could not separate HF with
reduced ejection fraction from HF with preserved ejection
fraction, a relevant distinction because, for the latter, evi-
dence is lacking or inconsistent with regard to the benefits of
beta-blockers, ACE inhibitors, and ARBs.23
We acknowledge that the study period was lengthy
(1988 through May 2015) and thus incorporated changes
in guidelines and prescribing practices over time, although
newer therapies were not yet in recommended use.
However, the majority of diagnoses were much later than
1988, with median diagnosis years of 2004 for inadequate
treatment groups and 2009–2010 for adequate treatment
groups. Moreover, whilst we did not assess drug doses,
any occurrence of under-dosing would increase the inci-
dence of treatment inadequacy. Information about the use
of non-pharmacological treatments, such as rehab and
smoking cessation aids, was not available in the CPRD
and OPCRD. Finally, as for all database studies, there is
the possibility of errors and omissions in recorded data.
Because of the multiple differences between adequate and
inadequate therapy groups, matched analyses and/or adjusted
models would be required to conduct a proper statistical com-
parison between these two groups to account for these differ-
ences. However, the process of matching the adequately to
inadequately treated patients would likely result in a large
number of patients being excluded, greatly reducing the gen-
eralizability of the results. Furthermore, given the large number
of candidate characteristics that could be included, and the size
of baseline differences, the process of developing adjusted
models would be complex andmay not produce robust results.
It would also be difficult to provide meaningful clinical inter-
pretation of these models because of the large baseline differ-
ences we identified.
Further studies are needed to understand the reasons
for the under-prescribing identified by this study as well as
by others.25,26,39 Longitudinal analysis techniques would
be useful in a future study to better understand temporal
differences in prescribing as relates to guideline adherence
and drug availability. This would illustrate how treatment
has changed over time and highlight any current treatment
disparities that remain to be addressed. Moreover, work is
needed to provide clinical education to improve and max-
imize appropriate prescribing for all patient subgroups, as
well as to encourage broader use of spirometric testing
when COPD is suspected. The optimal diagnostic and
therapeutic approaches to comorbid COPD and HF require
elucidation and implementation, as outlined in a recent call
for action.47 To that end, Roversi et al17 have proposed
diagnostic and treatment algorithms for patients suspected
of having comorbid COPD and HF that could be adapted
for wider dissemination.
Other important areas for further study are to determine
why clinicians may be reluctant to prescribe beta-blockers,
as well as whether there are actual benefits of treatment
with beta-blockers, in patients with COPD who have HF.48
The results of observational studies indicate there may be
beneficial effects of beta-blockers for patients with
COPD,49–51 and this question is being further explored in
a prospective randomized trial.52 Of note, in a recent pla-
cebo-controlled trial of metoprolol for patients with COPD
at increased risk of exacerbation—that specifically
excluded patients with established indications for a beta-
blocker—the risk of exacerbation was not lowered in the
metoprolol group.53 Finally, the safety of combined LABA
and LAMA for patients with comorbid COPD and HF also
requires further study.54,55
Conclusion
Many patients with comorbid COPD and HF receive
inadequate therapy after a new diagnosis of both condi-
tions. Our findings identify which patients are most likely
to be prescribed inadequate COPD therapy, including
women, current smokers, and non-obese patients, or inade-
quate HF therapy, including current smokers and non-
obese patients, after a new diagnosis in real-life clinical
practice. These findings support the need for improving
the equity of access to integrated care for all patients with
comorbid COPD and HF. This information could be used
to develop future guidelines to aid clinicians in making
treatment decisions for patients with these comorbid con-
ditions. A routine recommendation to examine for these
common comorbidities, and to provide adequate therapy
for both, should be addressed and expanded in COPD as
well as HF management guidelines.
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